Kevin Hershberger - President & Chief Executive Officer
Kevin is Lumicell’s Chief Executive Officer and brings over 25 years of global executive management experience in a variety of life science products and manufacturing companies with an extensive range of expertise and leadership responsibilities. He joined Lumicell as the Chief Financial Officer in 2018 and became President and CFO in 2019. Prior to Lumicell, Kevin most recently served as Chief Financial Officer of ReWalk Robotics where he built out the company’s finance function and launched a partnership with Harvard University’s Wyss Institute encompassing a broad licensing and collaboration agreement to develop a Softsuit Exoskeleton. Prior to ReWalk, he held leadership roles with NxStage Medical as the Vice President of Finance, Controller, and Chief Accounting Officer. Kevin also served in a variety of finance leadership roles at Boston Scientific.
W. David Lee - President & Chief Scientific Officer
David was the founding CEO of Lumicell and is now the Chief Scientific Officer. After creating T2 Biosystems (NASDAQ TTOO) he returned to the MIT Koch Institute to develop new technology that would address breast cancer which was responsible for his wife’s death. Lumicell is the embodiment of that goal. David has over 35 years of experience translating innovation into commercial successes. As a senior vice president and managing director at Arthur D. Little (ADL), he directed the technology and product development division, one of three major ADL business lines, and personally managed over 50 development and commercialization programs during his tenure. David and his associates taught product development and commercialization skills to Fortune 500 companies including ABB, General Electric, Carrier and Analog Devices. He has a B.S. and an M.S. in Mechanical Engineering from Massachusetts Institute of Technology and completed the intensive Advanced Management Program at Harvard Business School.
Jorge Ferrer, Ph.D. - Senior Vice President of Clinical Research and Strategy
Jorge leads the company's clinical research and strategy for the cancer applications and oversees the work with Lumicell’s academic collaborators conducting clinical studies. Jorge also manages Lumicell’s regulatory strategy, as well as the preparation of communications and reporting to the FDA. As Lumicell’s employee #2, he co-developed Lumicell’s cancer detection drug. During his post-doctoral tenure with Dr. Moungi Bawendi at Massachusetts Institute of Technology, he developed the prototype of the Lumicell imaging device and conducted the proof-of-concept experiments in mice and clinical trials in dogs. He holds a Ph.D. in Biological Engineering from MIT, an M.S. in Mechanical Engineering from MIT, and a B.S. in Mechanical Engineering from University of Puerto Rico Mayagüez. Prior to his post-graduate studies, Jorge worked as a Mechanical Design Engineer in the sensors and controls industry at Texas Instruments.
Daniel K. Harris, Ph.D. - Vice President of Pharmaceutical Development and CMC
Daniel is responsible for the development of Lumicell’s imaging drug including all aspects of manufacturing and CMC. He also leads regulatory strategy and is responsible for preparation of Lumicell’s NDA and other drug related regulatory filings. Prior to joining Lumicell, Daniel led the chemistry R&D group at QD Vision, a nanomaterials company developing fluorescent materials for the consumer display market, and supported the company through its acquisition by Samsung. Daniel received his Ph.D. from Massachusetts Institute of Technology, studying in the laboratory of Dr. Moungi Bawendi and developing fluorescent nanomaterials for in vivo imaging. He received a BS in Chemical Engineering from the University of Southern California. He is an author on 14 academic papers and an inventor on three patents.
Howard Hechler - Chief Business & Strategy Officer
Howard Hechler joined Lumicell in August of 2020 and brings to the company more than 15 years of focused life-sciences experience in M&A, strategy, and operations. His background spans a wide range of medical devices, diagnostics, pharmaceuticals, and drug-device combination products. Over his career, he has been involved in more than $500M in strategic transactions, as well as leading cross-functional teams to develop business cases and C-Suite strategic plans. Prior to joining Lumicell, Howard worked at Locust Walk, a boutique life sciences investment bank, where he used his background and experience to support the growth and extend the reach of the firm’s medical technology practice. Before joining Locust Walk, Howard served as Chief Business Officer for PolarityTE, a regenerative medicine company, where he was responsible for business development, marketing, sales, and market access/reimbursement strategies. Howard also worked in Business Development for Mallinckrodt Pharmaceuticals (a subsidiary of Coviden at the time), where he closed multiple co-promotions, financings, and divestitures. Howard then spent five years at Medtronic, running business development for the Surgical Technologies Business Unit ($2B in sales) and leading broad range of acquisitions, divestitures, licenses, distribution deals, and equity investments. Howard graduated cum laude with an AB in Near Eastern Language and Civilizations from Harvard University. He received both his Master of Business Administration and Juris Doctorate from the University of Virginia.
Sean Madden, Ph.D. - Senior Vice President of R&D, Oncology
Sean leads the refinement of Lumicell’s products and regulatory strategy to achieve FDA approval, the development of the next generation of Lumicell products, the management of Medical Affairs for ongoing and upcoming clinical trials, and the strategy, stewardship and growth of Lumicell’s intellectual property portfolio. Sean received his B.S. in chemistry from The University of Florida and his Ph.D. in analytical chemistry from The University of Arizona. He is an author on over 80 academic papers and an inventor on more than 10 patents and active applications. Sean has worked in biomedical measurements and medical devices for over 20 years in areas including drug discovery, non-invasive glucose detection, arterial blood gas sensing, cervical cancer screening, ophthalmology imaging, and interventional cardiology imaging. As Vice President of Research and Clinical at Infraredx, he developed the technology and trial strategy that led to unique and groundbreaking label claims for the detection of vulnerable plaque, commercialization and use in over 20,000 patients worldwide, and the acquisition of the company by Nipro Corporation.
Amee Patel Pant - Vice President of Human Resources
Amee has over 15 years of diverse human resources and management experience. Amee specializes in talent management, workforce development, strategic recruitment, leadership development and effective internal communications strategies. Amee has served on the senior management team at New England Office Supply (now WB Mason) leading Human Resources strategy. She founded Boylston Consulting Group to help companies advance organizational goals, implement change and drive top and bottom-line profit and revenue. She joined Lumicell in 2018 and in this capacity, she is responsible for all aspects of human resources initiatives including developing and implementing on-boarding, training, performance management, employee retention, benefits management, and employee relations strategies. She holds a B.A. in Economics and International Relations from University of Southern California and an MBA from Boston College.